Parlux Q2
This article was originally published in The Rose Sheet
Executive Summary
Sales slid 1% to $38.9 mil. for the quarter ended Sept. 30, 2006, while net income dropped 17% to $3.6 mil, Parlux reports March 30. For the six months, net sales were up 9% to $79.7 mil., with a net loss of $10.5 mil. due to a charge related to the company's June 2006 stock split, Parlux says. "I am pleased, after over four months of delays, we are moving forward with our reporting responsibilities," interim CEO Neil J. Katz remarks. In March, Nasdaq gave Parlux a March 31 deadline to report its second- and third-quarter financials before being delisted from the stock market. Parlux has since filed the former, but will not file the latter by deadline; it has asked Nasdaq for an April 16 extension. The firm cannot be sure that Nasdaq will grant the request but expects to be able to provide an update on the status of its Nasdaq listing next week. "I am optimistic that we will be issuing our third quarter results in a short period of time. We expect that our reporting delinquencies will shortly be a thing of the past," Katz said...
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.